Highlights from ASCO and EHA 2018

The Myeloma Patients Europe (MPE) team has been busy attending several important international conferences focusing on myeloma and AL amyloidosis. Main conferences attended were the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 and the European Haematology Association (EHA) Annual Congress 2018. These large-scale meetings bring together oncology and haematology professionals from across the globe to discuss the latest scientific and treatment developments in the field. The scientific and patient advocacy highlights are outlined…

MPE will hold a webinar on ASH 2017 highlights in myeloma

Myeloma Patients Europe will hold an online webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in San Diego (California, United States) in December 2017. The talk will be given by Dr María Victoria Mateos, Associate Professor of Hematology and Consultant. Physician of the Haematology Department at the University Hospital of Salamanca, Spain.

ASH Annual Meeting 2017 is about to start

The 59th American Society of Hematology (ASH) Annual Meeting will take place from 9 – 12 December in Atlanta, Georgia, United States (US). Myeloma Patients Europe (MPE) will be attending the meeting, alongside thousands of leading doctors, researchers and patient advocates in the field of blood cancer (hematology). Below we explain ASH and the importance of the meeting to patient advocates.  

Promising results of CAR T-Cell therapy in myeloma patients

53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) CHICAGO – In an early clinical trial, 33 out of 35 (94%) patients had clinical remission of myeloma upon receiving a new type of immunotherapy  ̶  chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein or BCMA. Most patients had only mild side effects. The study was presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting. “Although recent advances in chemotherapy have prolonged life expectancy in multiple myeloma, this cancer remains incurable,” said study author Wanhong Zhao, MD, PhD,…

Denosumab delays the time to first skeletal-related event in patients with myeloma

53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago – According to Phase 3 ‘482 study, the largest international multiple myeloma trial ever conducted with 1,718 patients involved, patients who receive denosumab (XGEVA) had a significantly lower rate of renal adverse events compared to zoledronic acid (10.0 percent versus 17.1 percent, p<0.001). The study met its primary endpoint, demonstrating denosumab is non-inferior to zoledronic acid in delaying the time to first on-study…